E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
Prithviraj Bose,Srdan Verstovsek,Jorge E. Cortes,Susan Tse,Yvonne Gasior,Nitin Jain,Elias Jabbour,Zeev Estrov,Yesid Alvarado,Courtney D. DiNardo,Naveen Pemmaraju,Steven M. Kornblau,Tapan M. Kadia,Naval Daver,Kiran Naqvi,Nicholas J. Short,Lucia Masarova,John Villareal,Sherry Pierce,Graciela M. Nogueras-Gonzalez,Xuelin Huang,Guillermo Garcia-Manero,Hagop M. Kantarjian,Farhad Ravandi +23 more
TL;DR: This year's finalists were: Srdan Verstovsek, Nitin Jain, Guillermo Garcia-Manero, Hagop M. Kantarjian, and Farhad Ravandi.
Journal ArticleDOI
Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
Nicholas J. Short,Elias Jabbour +1 more
TL;DR: By accurately identifying patients with persistent MRD who are at highest risk for relapse, the authors may be able to better design rational post-remission therapies using novel agents, such as inotuzumab ozogamicin, blinatumomab, and CD19-directed chimeric antigen receptor T cells, all of which have been shown to be effective in achieving MRD negativity, even in patients with relapsed or refractory disease.
Journal ArticleDOI
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
Maro Ohanian,Ana Tari Ashizawa,Guillermo Garcia-Manero,Naveen Pemmaraju,Tapan M. Kadia,Elias Jabbour,Farhad Ravandi,Gautam Borthakur,Michael Andreeff,Marina Konopleva,Miranda Lim,Sherry Pierce,Susan O'Brien,Yesid Alvarado,Srdan Verstovsek,William G. Wierda,Hagop M. Kantarjian,Jorge E. Cortes +17 more
TL;DR: The toxicity and tolerance of escalating doses of BP1001 monotherapy in patients with refractory or relapsed leukaemia were established, and the optimal biologically active dose of BP1000 was determined, defined as a 50% reduction in Grb2 expression in circulatingLeukaemia cells.
Journal ArticleDOI
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.
Qi Zhang,Ce Shi,Ce Shi,Lina Han,Lina Han,Nitin Jain,Kathryn G. Roberts,Helen Ma,Tianyu Cai,Antonio Cavazos,Yoko Tabe,Rodrigo Jacamo,Hong Mu,Yang Zhao,Jing Wang,Shuo-Chieh Wu,Fenglin Cao,Zhihong Zeng,Jin Zhou,Yingchang Mi,Elias Jabbour,Ross L. Levine,Sarah K. Tasian,Charles G. Mullighan,David M. Weinstock,David A. Fruman,Marina Konopleva +26 more
TL;DR: Combined inhibition of JAK/STAT and mTOR pathways by next-generation inhibitors had promising antileukemia efficacy in preclinical models of CRFL2-re Ph-like B-ALL.
Journal ArticleDOI
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
TL;DR: Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has further improved the treatment of CML.